深圳准肠康生物医学科技有限公司

BioMed Technology Holdings Limited, a startup nurtured by Hong Kong Science Park, was founded by a group of CUHK professors and alumni. The company specializes in microbiome science and bioinformatics and is dedicated to promoting precise and personalized microbiome-based interventions. These interventions are designed to restore the balance of the oral, skin, and gut microbiomes, thereby improving both physical and mental health.

Up to now, BioMed has successfully built a microbiome database comprising over 10,000 data points gathered from diverse regions across Asia. This valuable database continues to grow and serves as a promising cornerstone for the company's future R&D endeavors.

Commercially, BioMed has established collaborations with over 200 healthcare service providers in Hong Kong and directly markets its products to consumers through more than 260 retail outlets under the PGut Brand. Furthermore, the company has also expanded its operations to Macau, Mainland China, and Thailand.

BioMed has raised funds from Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA, CUHK Innovation Fund, The International Medical Co. Ltd. (TIMC) and Human Health Holdings Limited (1419.HK). DSS (NYEX: DSS), a US listed company is also a shareholder of BioMed.